EG24669A - Antivral azaindole derivatives - Google Patents

Antivral azaindole derivatives

Info

Publication number
EG24669A
EG24669A EG20010152A EG20010152A EG24669A EG 24669 A EG24669 A EG 24669A EG 20010152 A EG20010152 A EG 20010152A EG 20010152 A EG20010152 A EG 20010152A EG 24669 A EG24669 A EG 24669A
Authority
EG
Egypt
Prior art keywords
antivral
azaindole derivatives
azaindole
derivatives
antivral azaindole
Prior art date
Application number
EG20010152A
Other languages
English (en)
Inventor
Tao Wang
Owen B Wallace
Zhongxing Zhang
Nicholas A Meanwell
John A Bender
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22675206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24669(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of EG24669A publication Critical patent/EG24669A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EG20010152A 2000-02-22 2001-02-19 Antivral azaindole derivatives EG24669A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18400400P 2000-02-22 2000-02-22

Publications (1)

Publication Number Publication Date
EG24669A true EG24669A (en) 2010-04-11

Family

ID=22675206

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20010152A EG24669A (en) 2000-02-22 2001-02-19 Antivral azaindole derivatives

Country Status (31)

Country Link
US (1) US20020061892A1 (de)
EP (1) EP1257276B1 (de)
JP (1) JP3868814B2 (de)
KR (1) KR100496574B1 (de)
CN (1) CN1404392A (de)
AR (1) AR029469A1 (de)
AT (1) ATE314072T1 (de)
AU (2) AU3289501A (de)
BR (1) BRPI0108485B1 (de)
CA (1) CA2400700C (de)
CO (1) CO5271657A1 (de)
CY (1) CY1107460T1 (de)
DE (1) DE60116260T2 (de)
DK (1) DK1257276T3 (de)
EG (1) EG24669A (de)
ES (1) ES2254367T3 (de)
HU (1) HU229992B1 (de)
IL (1) IL150734A0 (de)
MX (1) MXPA02008113A (de)
MY (1) MY128458A (de)
NO (1) NO323564B1 (de)
NZ (1) NZ520317A (de)
PE (1) PE20020786A1 (de)
PL (1) PL357434A1 (de)
PT (1) PT1257276E (de)
RU (1) RU2259372C2 (de)
TR (1) TR200201961T2 (de)
TW (1) TWI293629B (de)
UY (1) UY26593A1 (de)
WO (1) WO2001062255A1 (de)
ZA (1) ZA200206073B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287900B6 (sk) * 2001-02-02 2012-03-02 Bristol-Myers Squibb Company Substituted azaindolexoacetic piperazine derivatives and pharmaceutical composition containing thereof
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
US20040162298A1 (en) * 2002-02-23 2004-08-19 Hsu-Tso Ho Method of treating HIV infection by preventing interaction of CD4 and gp120
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
UA88297C2 (ru) * 2004-03-15 2009-10-12 Бристол-Майэрс Сквибб Компани Пиперазиновые пролекарства и замещенные пиперидиновые антивирусные средства
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20050252408A1 (en) * 2004-05-17 2005-11-17 Richardson H W Particulate wood preservative and method for producing same
BRPI0511874A (pt) 2004-06-09 2008-01-15 Glaxo Group Ltd derivados da pirrolopiridina
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7183284B2 (en) * 2004-12-29 2007-02-27 Bristol-Myers Squibb Company Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
US7601715B2 (en) 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
US20070026441A1 (en) 2005-07-22 2007-02-01 Olson William C Methods for reducing viral load in HIV-1-infected patients
US7598380B2 (en) 2005-08-03 2009-10-06 Bristol-Myers Squibb Company Method of preparation of azaindole derivatives
US7396830B2 (en) * 2005-10-04 2008-07-08 Bristol-Myers Squibb Company Piperazine amidines as antiviral agents
ES2351940T3 (es) * 2005-11-18 2011-02-14 F. Hoffmann-La Roche Ag Derivados de azaindol-2-carboxamida.
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
MY148901A (en) * 2007-06-18 2013-06-14 Sanofi Aventis Pyrrole derivatives as p2y12 antagonists
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
WO2009011912A1 (en) * 2007-07-18 2009-01-22 Bristol-Myers Squibb Company A composition for treating hiv comprising virus-like particles
BRPI0906727A2 (pt) 2008-01-31 2015-08-04 Sanofi Aventis Azaindol-3-carboxamidas cíclicas, sua preparação e seu uso como produtos farmacêuticos
HRP20120441T1 (hr) * 2008-09-04 2012-06-30 Bristol-Myers Squibb Company Stabilna farmaceutska smjesa za optimiziranu dopremu inhibitora prianjanja hiv-a
EA031116B1 (ru) 2009-04-03 2018-11-30 Ф. Хоффманн-Ля Рош Аг КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ
UA105813C2 (uk) 2009-11-06 2014-06-25 Плексікон, Інк. Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти)
ES2585396T3 (es) 2010-12-02 2016-10-05 VIIV Healthcare UK (No.5) Limited Alquilamidas como inhibidores de la unión del VIH
PL2672967T3 (pl) 2011-02-07 2019-04-30 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania ku temu
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
EP2696937B1 (de) 2011-04-12 2017-05-17 VIIV Healthcare UK (No.5) Limited Thioamid-, amidoxim- und amidrazonderivate als hiv-bindungsinhibitoren
ES2609579T3 (es) 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
US8835454B2 (en) 2011-08-29 2014-09-16 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as HIV attachment inhibitors
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN102746295B (zh) * 2012-06-20 2014-10-15 上海阿达玛斯试剂有限公司 4位取代-7-氮杂吲哚的制备方法
WO2014025852A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Tricyclic alkene derivatives as hiv attachment inhibitors
US9505752B2 (en) 2012-08-09 2016-11-29 Viiv Healthcare Uk (No. 5) Limited Piperidine amide derivatives as HIV attachment inhibitors
CN109528749B (zh) * 2017-09-22 2023-04-28 上海交通大学医学院附属瑞金医院 长链非编码rna-h19在制备治疗垂体瘤药物中的用途
CA3196620A1 (en) 2020-10-05 2022-04-14 Enliven Therapeutics, Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
CN112430223B (zh) * 2020-11-24 2022-11-25 中国人民解放军海军军医大学 一类取代苯甲酰哌嗪类化合物及其应用
CN115855899B (zh) * 2022-11-24 2025-06-10 常熟理工学院 一种荧光探针检测二氧化硫衍生物的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07110852B2 (ja) * 1989-12-28 1995-11-29 ジ・アップジョン・カンパニー 二芳香族置換抗ａｉｄｓ化合物
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion

Also Published As

Publication number Publication date
EP1257276A4 (de) 2004-10-27
CA2400700C (en) 2010-10-26
WO2001062255A1 (en) 2001-08-30
NO323564B1 (no) 2007-06-11
AU3289501A (en) 2001-09-03
EP1257276A1 (de) 2002-11-20
ZA200206073B (en) 2003-10-30
TR200201961T2 (tr) 2002-12-23
CO5271657A1 (es) 2003-04-30
TWI293629B (de) 2008-02-21
NO20023981L (no) 2002-10-17
CA2400700A1 (en) 2001-08-30
DK1257276T3 (da) 2006-04-10
CN1404392A (zh) 2003-03-19
MY128458A (en) 2007-02-28
KR20020073598A (ko) 2002-09-27
US20020061892A1 (en) 2002-05-23
HU229992B1 (en) 2015-04-28
AR029469A1 (es) 2003-07-02
PE20020786A1 (es) 2002-09-06
EP1257276B1 (de) 2005-12-28
HK1052132A1 (en) 2003-09-05
ES2254367T3 (es) 2006-06-16
PL357434A1 (en) 2004-07-26
PT1257276E (pt) 2006-05-31
JP2003523392A (ja) 2003-08-05
JP3868814B2 (ja) 2007-01-17
DE60116260D1 (de) 2006-02-02
ATE314072T1 (de) 2006-01-15
RU2002125494A (ru) 2004-03-20
RU2259372C2 (ru) 2005-08-27
DE60116260T2 (de) 2006-08-31
BRPI0108485B1 (pt) 2016-08-23
NO20023981D0 (no) 2002-08-21
BR0108485A (pt) 2003-04-22
HUP0301508A2 (hu) 2003-09-29
NZ520317A (en) 2004-05-28
UY26593A1 (es) 2001-09-28
HUP0301508A3 (en) 2004-08-30
IL150734A0 (en) 2003-02-12
CY1107460T1 (el) 2012-12-19
MXPA02008113A (es) 2003-01-28
KR100496574B1 (ko) 2005-06-22
AU2001232895B2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
EG24669A (en) Antivral azaindole derivatives
AU2001295992A1 (en) Imidazopyridine derivatives
IL152783A0 (en) 2-aminocarbonyl-9h-purine derivatives
HRP20030055A2 (en) 4-phenyl-pyridine derivatives
IL150841A0 (en) 1h-imidazopyridine derivatives
IL155885A0 (en) Substituted imidazopyridines
IL151919A0 (en) Imidazopyridine derivatives and triazolpyrimidine derivatives
IL155974A0 (en) Novel pyridine-substituted pyrazolopyridine derivatives
AU2002216028A1 (en) Novel carbamate-substituted pyrazolopyridine derivatives
AU2002221827A1 (en) Novel lactame-substituted pyrazolopyridine derivatives
AP2002002649A0 (en) Novel phenylpropargylether derivatives
IL152581A0 (en) Phenylglycine derivatives
PL354600A1 (en) Naphthyridine derivatives
AU1397802A (en) Substituted c-cyclohexylmethylamine derivatives
PL356565A1 (en) Aminosulfonylbiphenyl derivatives
IL150557A0 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives
IL155106A0 (en) Substituted 1-aminobutan-3-ol derivatives
IL150558A0 (en) Aminomethyl-phenyl-cyclohexanone derivatives
IL155104A0 (en) 5-amino-1-pentene-3-ol substituted derivatives
IL151598A0 (en) 2-phenylpyran-4-one derivatives
GB0021639D0 (en) Maurotoxin derivatives
SI1322590T1 (sl) Substituirani 5-amino-1-penten-3-olni derivati
SI1246793T1 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives